SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Maze Therapeutics, a company translating genetic insights into new precision medicines, today revealed its first three lead therapeutic candidates in ...

In addition, Maze Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,312,500 shares of common stock at the initial public offering price, less underwriting ...

Maze expects to report initial data, including proof-of-mechanism biomarkers, in the second half of 2025. Based on Phase 1 results, Maze plans to initiate two parallel Phase 2 clinical trials of ...

Mazarin Inc. ("Mazarin" or the "Company") announced today that its subsidiary, Asbestos Corporation Limited ("ACL") (TSXV: MAZ.H), has obtained an Amended and Restated Initial Order (the "ARIO") from ...

SOUTH SAN FRANCISCO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop ...

Mazarin Inc. ("Mazarin" or the "Company") announced today that its subsidiary, Asbestos Corporation Limited ("ACL") (TSXV: MAZ.H), has obtained an Amended and Restated Initial Order (the "ARIO ...